Literature DB >> 3162316

Antibodies to cholesterol.

G M Swartz1, M K Gentry, L M Amende, E J Blanchette-Mackie, C R Alving.   

Abstract

Cholesterol-dependent complement activation has been proposed as a factor that might influence the pathogenesis of atherosclerosis. Although antibodies to cholesterol conjugates have been reported, cholesterol is widely regarded as a poorly immunogenic substance. Monoclonal IgM complement-fixing antibodies to cholesterol were obtained in the present study after immunizing mice with liposomes containing high amounts of cholesterol (71 mol % relative to phosphatidylcholine) and lipid A as an adjuvant. Clones were selected for the ability of secreted antibodies to react with liposomes containing 71% cholesterol but not with liposomes containing 43% cholesterol. The antibodies also reacted with crystalline cholesterol in a solid-phase enzyme-linked immunosorbent assay. Binding of monoclonal antibodies to the surface of crystalline cholesterol was demonstrated by electron microscopy by utilizing a second antibody (anti-IgM) labeled with colloidal gold. The immunization period required to induce monoclonal antibodies was very short (3 days) and a high fraction of the hybrid cells (at least 70%) were secreting detectable antibodies to cholesterol. The results demonstrate that cholesterol can be a highly immunogenic molecule and that complement-fixing antibodies to cholesterol can be readily obtained.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3162316      PMCID: PMC279889          DOI: 10.1073/pnas.85.6.1902

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  On the immune precipitation of phosphorylcholine lipids with TEPC 15 mouse myeloma protein and with anti-lecithin sera from guinea pigs.

Authors:  B Niedieck; U Kuck; H Gardemin
Journal:  Immunochemistry       Date:  1978-07

2.  A simple radioimmunoassay to determine binding of antibodies to lipid antigens.

Authors:  M Smolarsky
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

3.  Activation of the alternative pathway of complement by microcrystalline cholesterol.

Authors:  P Hasselbacher; J L Hahn
Journal:  Atherosclerosis       Date:  1980-10       Impact factor: 5.162

4.  Immunochemical properties of phosphatidyl cholesterol and its homologue.

Authors:  I Hara; T Muramatsu; T Fukuda; J Sato
Journal:  Chem Phys Lipids       Date:  1979-01       Impact factor: 3.329

5.  Cholesterol-lipid interactions in membranes. The saturation concentration of cholesterol in bilayers of various lipids.

Authors:  H Reiber
Journal:  Biochim Biophys Acta       Date:  1978-09-11

6.  Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes.

Authors:  C R Alving; R L Richards; A A Guirguis
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

7.  C3 deposition in cholesterol-induced atherosclerosis in rabbits: a possible etiologic role for complement in atherogenesis.

Authors:  A S Pang; A Katz; J O Minta
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

8.  The stability and structure of cholesterol-rich codispersions of cholesterol and phosphatidylcholine.

Authors:  J J Collins; M C Phillips
Journal:  J Lipid Res       Date:  1982-02       Impact factor: 5.922

9.  Cholesterol and atheroma lipids activate complement and stimulate granulocytes. A possible mechanism for amplification of ischemic injury in atherosclerotic states.

Authors:  D E Hammerschmidt; C S Greenberg; O Yamada; P R Craddock; H S Jacob
Journal:  J Lab Clin Med       Date:  1981-07

10.  Properties of mixed vesicles of lecithin: cholesterol up to a 1:2 molar ratio.

Authors:  B Lundberg
Journal:  Chem Phys Lipids       Date:  1977-03       Impact factor: 3.329

View more
  20 in total

1.  Detection of immunoglobulin G antibodies to cholesterol in antisera to mycoplasmas.

Authors:  T Watanabe; T Kumazawa
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

Review 2.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

Review 3.  What else can the immune system recognize?

Authors:  D Izhaky; I Pecht
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

Review 4.  Review of progress in sterol oxidations: 1987-1995.

Authors:  L L Smith
Journal:  Lipids       Date:  1996-05       Impact factor: 1.880

5.  Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.

Authors:  S Hörkkö; E Miller; E Dudl; P Reaven; L K Curtiss; N J Zvaifler; R Terkeltaub; S S Pierangeli; D W Branch; W Palinski; J L Witztum
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 6.  Free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis.

Authors:  B Halliwell
Journal:  Br J Exp Pathol       Date:  1989-12

7.  Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.

Authors:  Gary R Matyas; Alexander V Mayorov; Kenner C Rice; Arthur E Jacobson; Kejun Cheng; Malliga R Iyer; Fuying Li; Zoltan Beck; Kim D Janda; Carl R Alving
Journal:  Vaccine       Date:  2013-04-23       Impact factor: 3.641

8.  Antibodies to nystatin demonstrate polyene sterol specificity and allow immunolabeling of sterols in Saccharomyces cerevisiae.

Authors:  H M Walker-Caprioglio; J M MacKenzie; L W Parks
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

9.  Synthesis of β-cyclodextrin conjugated superparamagnetic iron oxide nanoparticles for selective binding and detection of cholesterol crystals.

Authors:  Hongguang Li; Mohammad H El-Dakdouki; David C Zhu; George S Abela; Xuefei Huang
Journal:  Chem Commun (Camb)       Date:  2012-01-16       Impact factor: 6.222

10.  Reversible inhibition of oligodendrocyte progenitor differentiation by a monoclonal antibody against surface galactolipids.

Authors:  R Bansal; S E Pfeiffer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.